Clinical Trial News and Research

RSS

Analysis of clinical trials reveals urgent need to increase Alzheimer's drug development

Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments.

3 Jul 2014

Combination of cognitive behavioral therapy and medication reduces relapse in depressed youths

Cognitive behavioral therapy in addition to medication improves the long-term success of treatment for children and adolescents suffering from depression, a new UT Southwestern Medical Center study indicates.

3 Jul 2014

Testosterone therapy does not increase men's risk for heart attack, shows UTMB study

Testosterone prescriptions for older men in the United States have increased more than three-fold over the past decade. Recent studies linking testosterone use with increased risk of heart attack and stroke have caused widespread concern among patients and their families.

2 Jul 2014

Study explores neurological outcomes in patients treated for traumatic brain injury

In patients with a traumatic brain injury (TBI), neither the administration of the hormone erythropoietin (EPO) or maintaining a higher hemoglobin concentration through blood transfusion resulted in improved neurological outcome at 6 months, according to a study in the July 2 issue of JAMA.

2 Jul 2014

New gene therapy for Acute Intermittent Porphyria

Angeles suffers from a severe and rare genetic disease called Acute Intermittent Porphyria (AIP). This means, one of her genes restrains her liver to produce a specific protein needed for the metabolism of the blood. During an AIP attack Angeles usually feels intense abdominal pain, and her mental status changes. Women live at an increased risk to trigger the symptoms, because porphyria is related to the menstrual cycle.

2 Jul 2014

New smartphone-based system detects changes in patients' behavioral patterns

Mental illness accounts for 90 percent of all reported suicides and places the largest burden of any disease on social and economic infrastructures worldwide, according to the World Health Organization.

1 Jul 2014

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected.

1 Jul 2014

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI BioPharma Corp. announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis.

From Baxter International Inc. 1 Jul 2014

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Ipsen today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration for Somatuline Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

1 Jul 2014

New approach may help develop more effective immunotherapy for metastatic melanoma

A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy.

1 Jul 2014

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

Aclaris Therapeutics, Inc. today announced positive results from a Phase 2 clinical trial of the Company's lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK), one of the most common types of skin tumors.

1 Jul 2014

UCSF researchers complete first Internet-based clinical trial for children with autism

UC San Francisco researchers have completed the first Internet-based clinical trial for children with autism, establishing it as a viable and cost effective method of conducting high-quality and rapid clinical trials in this population.

1 Jul 2014

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma.

1 Jul 2014

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Therapeutics, LLC, today announced that the Company has entered into a transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for AcipHex® Sprinkle™ (rabeprazole sodium), Delayed-Release Capsules, 5 mg and 10 mg, for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks.

30 Jun 2014

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

30 Jun 2014

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company's investigational anti-PD-1 antibody, for the treatment of advanced melanoma.

30 Jun 2014

IXICO and VirtualScopics jointly lease office space in New Hope, Pennsylvania

VirtualScopics, Inc., a leading provider of clinical trial imaging solutions, and IXICO plc (AIM: IXI), the brain health company, announced today they are jointly leasing 2,190 sq. ft. of office space in New Hope, Pennsylvania, strategically located within the big pharma corridor that runs through New Jersey and Pennsylvania.

30 Jun 2014

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Genervon Biopharmaceuticals LLC ("Genervon") today announced that it has analyzed and generated a Biomarker Data Report for its recent Phase 2a clinical trial for ALS disease modification.

30 Jun 2014

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal.

28 Jun 2014

Thoratec commences CE Mark Clinical Trial for HeartMate III chronic left ventricular assist system

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that its CE Mark Clinical Trial for HeartMate III™ commenced with the first patient implanted with this new device.

27 Jun 2014

Clinical Trial News and Research

Analysis of clinical trials reveals urgent need to increase Alzheimer's drug development

Combination of cognitive behavioral therapy and medication reduces relapse in depressed youths

Testosterone therapy does not increase men's risk for heart attack, shows UTMB study

Study explores neurological outcomes in patients treated for traumatic brain injury

New gene therapy for Acute Intermittent Porphyria

New smartphone-based system detects changes in patients' behavioral patterns

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

New approach may help develop more effective immunotherapy for metastatic melanoma

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

UCSF researchers complete first Internet-based clinical trial for children with autism

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

IXICO and VirtualScopics jointly lease office space in New Hope, Pennsylvania

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

Thoratec commences CE Mark Clinical Trial for HeartMate III chronic left ventricular assist system

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery